Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Inspire Investing LLC

Inspire Investing LLC lowered its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 38,410 shares of the biopharmaceutical company’s stock after selling 1,981 shares during the period. Inspire Investing LLC’s holdings in Catalyst Pharmaceuticals were worth $802,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CPRX. Jane Street Group LLC boosted its stake in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after buying an additional 285,564 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Catalyst Pharmaceuticals by 9.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after buying an additional 263,099 shares during the last quarter. Walleye Capital LLC acquired a new position in Catalyst Pharmaceuticals during the third quarter worth $4,936,000. AQR Capital Management LLC boosted its stake in Catalyst Pharmaceuticals by 87.1% during the second quarter. AQR Capital Management LLC now owns 488,386 shares of the biopharmaceutical company’s stock worth $7,565,000 after buying an additional 227,321 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Catalyst Pharmaceuticals by 146.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock worth $7,285,000 after buying an additional 217,956 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Bank of America reaffirmed a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Truist Financial upped their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, HC Wainwright upped their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and an average price target of $32.86.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now owns 51,391 shares in the company, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $1,754,140 in the last quarter. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Trading Up 0.2 %

CPRX stock opened at $22.55 on Friday. The company has a market capitalization of $2.69 billion, a PE ratio of 19.11, a P/E/G ratio of 2.28 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.12 and a 12-month high of $24.27. The business’s fifty day moving average price is $21.79 and its 200 day moving average price is $20.45.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.